Year-over-year articles
LYTIX BIOPHARMA ASA
23 crawlable comparisons of consecutive annual reports.
Full company analysis · Org.nr 985 889 635
Shrank 100% on revenue, stronger earnings, cash halved-plus
Comparing Årsregnskap 2025 with 2024 for LYTIX BIOPHARMA ASA. Revenue 11.13m NOK → 11.1k NOK (-99.9%). Net result -94.27m NOK → -59.98m NOK. Equity 107.89m…
Grew 179% on revenue, fresh owner capital
Comparing Årsregnskap 2024 with 2023 for LYTIX BIOPHARMA ASA. Revenue 3.99m NOK → 11.13m NOK (+179.0%). Net result -87.90m NOK → -94.27m NOK. Equity 51.32m…
Shrank 77% on revenue, weaker earnings, cash halved-plus
Comparing Årsregnskap 2023 with 2022 for LYTIX BIOPHARMA ASA. Revenue 17.27m NOK → 3.99m NOK (-76.9%). Net result -56.01m NOK → -87.90m NOK. Equity 135.13m…
Shrank 33% on revenue, cash halved-plus
Comparing Årsregnskap 2022 with 2021 for LYTIX BIOPHARMA ASA. Revenue 25.83m NOK → 17.27m NOK (-33.1%). Net result -48.05m NOK → -56.01m NOK. Equity 189.62m…
Grew 287% on revenue, fresh owner capital
Comparing Årsregnskap 2021 with 2020 for LYTIX BIOPHARMA ASA. Revenue 6.68m NOK → 25.83m NOK (+286.7%). Net result -42.09m NOK → -48.05m NOK. Equity 19.89m…
Weaker earnings, fresh owner capital
Comparing Årsregnskap 2020 with 2019 for LYTIX BIOPHARMA ASA. Revenue 6.70m NOK → 6.68m NOK (-0.3%). Net result -33.23m NOK → -42.09m NOK. Equity 14.39m NOK…
Shrank 43% on revenue, stronger earnings, cash halved-plus
Comparing Årsregnskap 2019 with 2018 for LYTIX BIOPHARMA ASA. Revenue 11.84m NOK → 6.70m NOK (-43.4%). Net result -61.52m NOK → -33.23m NOK. Equity 41.05m…
Shrank 16% on revenue, fresh owner capital
Comparing Årsregnskap 2018 with 2017 for LYTIX BIOPHARMA ASA. Revenue 14.15m NOK → 11.84m NOK (-16.3%). Net result -63.36m NOK → -61.52m NOK. Equity 11.79m…
Grew 7% on revenue
Comparing Årsregnskap 2017 with 2016 for LYTIX BIOPHARMA ASA. Revenue 13.17m NOK → 14.15m NOK (+7.4%). Net result -67.83m NOK → -63.36m NOK. Equity 29.79m…
Shrank 13% on revenue, weaker earnings
Comparing Årsregnskap 2016 with 2015 for LYTIX BIOPHARMA ASA. Revenue 15.22m NOK → 13.17m NOK (-13.5%). Net result -55.19m NOK → -67.83m NOK. Equity 88.80m…
Grew 136% on revenue, weaker earnings, fresh owner capital
Comparing Årsregnskap 2015 with 2014 for LYTIX BIOPHARMA ASA. Revenue 6.44m NOK → 15.22m NOK (+136.4%). Net result -39.54m NOK → -55.19m NOK. Equity 59.65m…
Grew 12718% on revenue, cash halved-plus, fresh owner capital
Comparing Årsregnskap 2014 with 2013 for LYTIX BIOPHARMA ASA. Revenue 50.2k NOK → 6.44m NOK (+12718.1%). Equity 47.22m NOK → 59.65m NOK.
Fresh owner capital
Comparing Årsregnskap 2013 with 2012 for LYTIX BIOPHARMA ASA. Revenue 50.5k NOK → 50.2k NOK (-0.5%). Equity 17.95m NOK → 47.22m NOK.
Shrank 6% on revenue, cash halved-plus
Comparing Årsregnskap 2012 with 2011 for LYTIX BIOPHARMA ASA. Revenue 53.9k NOK → 50.5k NOK (-6.3%). Equity 40.33m NOK → 17.95m NOK.
Mixed movements in the accounts
Comparing Årsregnskap 2011 with 2010 for LYTIX BIOPHARMA ASA. Revenue 0 NOK → 53.9k NOK. Equity 79.59m NOK → 40.33m NOK.
Mixed movements in the accounts
Comparing Årsregnskap 2010 with 2009 for LYTIX BIOPHARMA ASA. Equity 72.04m NOK → 79.59m NOK.
Stronger earnings
Comparing Årsregnskap 2009 with 2008 for LYTIX BIOPHARMA ASA. Net result -34.29m NOK → -26.37m NOK. Equity 83.48m NOK → 72.04m NOK.
Shrank 100% on revenue, weaker earnings, cash halved-plus
Comparing Årsregnskap 2008 with 2007 for LYTIX BIOPHARMA ASA. Revenue 231.7k NOK → 300 NOK (-99.9%). Net result -15.16m NOK → -34.29m NOK. Equity 48.42m NOK…
Shrank 19% on revenue, weaker earnings
Comparing Årsregnskap 2007 with 2006 for LYTIX BIOPHARMA ASA. Revenue 285.0k NOK → 231.7k NOK (-18.7%). Net result -8.09m NOK → -15.16m NOK. Equity 15.90m…
Grew 1335% on revenue, weaker earnings
Comparing Årsregnskap 2006 with 2005 for LYTIX BIOPHARMA ASA. Revenue 19.9k NOK → 285.0k NOK (+1335.1%). Net result -4.20m NOK → -8.09m NOK. Equity 4.34m…
Weaker earnings, fresh owner capital
Comparing Årsregnskap 2005 with 2004 for LYTIX BIOPHARMA ASA. Net result -2 144 NOK → -4.20m NOK. Equity 3 799 NOK → 4.34m NOK.
Slipped into loss, fresh owner capital
Comparing Årsregnskap 2004 with 2003 for LYTIX BIOPHARMA ASA. Net result +770 NOK → -2 144 NOK. Equity 55 NOK → 3 799 NOK.
First published accounts
First year in the published series for LYTIX BIOPHARMA ASA (2003). No prior-year comparative in this dataset.